Considering the alarming rate of diabetic patients becoming blind after retinal edema formation, and the important risks of ocular complications due to the low specificity of the current glucocorticoid (GC) treatment, it is imperative to bring together all the necessary means for the development of novel therapies with better specificity, efficiency and limited secondary effects. To that end, it is crucial to fill the gap in the fundamental knowledge of diabetic macular edema (DME) physiopathology. By taking advantage of an existing beneficial but imperfect anti-edematous therapy (low specificity), we propose to use state-of-the-art methods to perform a wide and unique study on the mechanisms i) involved in diabetic retinopathy ii) and regulated by the corticosteroids, with the aim to potentiate the therapeutic effect of GCs, for a real restoration of vision in DME patients.
Field of science
- /medical and health sciences/clinical medicine/endocrinology/diabetes
- /medical and health sciences/clinical medicine/ophthalmology/retinopathy
Call for proposal
See other projects for this call